RecruitingPhase 1NCT07444385
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions
Sponsor
Addpharma Inc.
Enrollment
44 participants
Start Date
Feb 26, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects
Eligibility
Sex: MALEMin Age: 19 Years
Inclusion Criteria2
- Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit
Exclusion Criteria2
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAD-116, AD-1161
Single-dose oral administration of AD-116 or AD-1161, according to randomized sequence.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07444385
Related Trials
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT0651114120 locations
Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia
NCT075698741 location
BPH Global Registry
NCT0554320026 locations
Ambulatory Long Length URodynamics Evaluation
NCT074250157 locations
The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
NCT072146751 location